14,085 Shares in Progyny, Inc. (NASDAQ:PGNY) Purchased by Quantessence Capital LLC

Quantessence Capital LLC bought a new stake in shares of Progyny, Inc. (NASDAQ:PGNY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 14,085 shares of the company’s stock, valued at approximately $243,000.

A number of other large investors also recently added to or reduced their stakes in PGNY. Signaturefd LLC raised its position in shares of Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after buying an additional 1,355 shares during the last quarter. GAMMA Investing LLC lifted its stake in Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after purchasing an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after purchasing an additional 1,526 shares in the last quarter. Caitlin John LLC boosted its holdings in shares of Progyny by 2,974.8% during the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after purchasing an additional 3,183 shares during the last quarter. Finally, Natixis purchased a new position in shares of Progyny during the fourth quarter valued at about $69,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PGNY. Bank of America increased their price target on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. JPMorgan Chase & Co. raised their target price on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Canaccord Genuity Group upped their price target on shares of Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a research note on Friday, February 28th. Finally, BTIG Research raised shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a research note on Monday, March 31st. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $23.64.

Progyny Stock Up 2.3 %

PGNY stock opened at $21.87 on Wednesday. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $33.84. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of 37.71, a PEG ratio of 2.39 and a beta of 1.33. The business’s fifty day simple moving average is $21.93 and its two-hundred day simple moving average is $18.94.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.